Know Cancer

or
forgot password

Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib


N/A
N/A
N/A
Not Enrolling
Both
Cholangiocarcinoma

Thank you

Trial Information

Chart Review on Patients With Unresectable/Metastatic Cholangiocarcinoma Treated in the UNM Cancer Center With a Combination of Irinotecan, Capecitabine and Celecoxib


As above.


Inclusion Criteria:



- Patients with unresectable/metastatic cholangiocarcinoma treated in the UNM Cancer
Center with a combination of irinotecan, capecitabine and celecoxib.

Exclusion Criteria:

- Not specified.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Principal Investigator

Fa-Chyi Lee, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of New Mexico

Authority:

United States: Institutional Review Board

Study ID:

4504C

NCT ID:

NCT00320918

Start Date:

November 2005

Completion Date:

October 2006

Related Keywords:

  • Cholangiocarcinoma
  • Unresectable/metastatic cholangiocarcinoma
  • Cancer
  • Chart Review
  • Cholangiocarcinoma

Name

Location

University of New MexicoAlbuquerque, New Mexico  87131